Literature DB >> 15917536

Cellular uptake and efflux of azithromycin, erythromycin, clarithromycin, telithromycin, and cethromycin.

Martina Bosnar1, Zeljko Kelnerić, Vesna Munić, Vesna Eraković, Michael J Parnham.   

Abstract

Macrolide antibiotics have an outstanding ability to concentrate within host cells, particularly phagocytes. In the study described in this paper five different macrolide antibiotics were compared regarding the uptake and release kinetics in human peripheral blood polymorphonuclear neutrophils (PMNs) and three different cell lines, two phagocytic cell lines (RAW 264.7 and THP-1) and an epithelial cell line (MDCK). Based on the results obtained, the substances tested could be clustered into different groups. Azithromycin constituted the first group, characterized by rapid and nonsaturable uptake into phagocytic cells and a high degree of retention in the preloaded cells. The second group included erythromycin and clarithromycin. These two substances do not exhibit cell specificity; consequently, they are taken up to a similar extent and are released by all cell types studied. Ketolides constituted the last group. Their uptake was saturable in cells of monocytic lineage as well as in nondifferentiated cells of myeloid lineage, and they were rapidly released from all the cell lines studied. However, in PMNs, ketolide uptake was not saturable; and unlike telithromycin, cethromycin rapidly egressed from the loaded cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15917536      PMCID: PMC1140530          DOI: 10.1128/AAC.49.6.2372-2377.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  32 in total

1.  In vitro activity of ABT 773, a new ketolide antibiotic, against Chlamydia pneumoniae.

Authors:  S Strigl; P M Roblin; T Reznik; M R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

2.  Intracellular bioactivity of macrolides.

Authors:  Marie Thérèse Labro
Journal:  Clin Microbiol Infect       Date:  1996-03       Impact factor: 8.067

3.  Uptake, transport, and delivery of antimicrobial agents by human polymorphonuclear neutrophils.

Authors:  G L Mandell; E Coleman
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

4.  Interactions between HMR 3647, a new ketolide, and human polymorphonuclear neutrophils.

Authors:  D Vazifeh; A Preira; A Bryskier; M T Labro
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

5.  The new ketolide HMR3647 accumulates in the azurophil granules of human polymorphonuclear cells.

Authors:  C Miossec-Bartoli; L Pilatre; P Peyron; E N N'Diaye; V Collart-Dutilleul; I Maridonneau-Parini; A Diu-Hercend
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

6.  Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens.

Authors:  A Denis; C Agouridas; J M Auger; Y Benedetti; A Bonnefoy; F Bretin; J F Chantot; A Dussarat; C Fromentin; S G D'Ambrières; S Lachaud; P Laurin; O Le Martret; V Loyau; N Tessot; J M Pejac; S Perron
Journal:  Bioorg Med Chem Lett       Date:  1999-11-01       Impact factor: 2.823

7.  Investigation of dirithromycin and erythromycylamine uptake by human neutrophils in vitro.

Authors:  E M Mtairag; H Abdelghaffar; M T Labro
Journal:  J Antimicrob Chemother       Date:  1994-03       Impact factor: 5.790

Review 8.  Tissue kinetics of telithromycin, the first ketolide antibacterial.

Authors:  C Muller-Serieys; J Andrews; F Vacheron; C Cantalloube
Journal:  J Antimicrob Chemother       Date:  2004-01-16       Impact factor: 5.790

9.  Synthesis, in vitro and in vivo activity of novel 9-deoxo-9a-AZA-9a-homoerythromycin A derivatives; a new class of macrolide antibiotics, the azalides.

Authors:  G M Bright; A A Nagel; J Bordner; K A Desai; J N Dibrino; J Nowakowska; L Vincent; R M Watrous; F C Sciavolino; A R English
Journal:  J Antibiot (Tokyo)       Date:  1988-08       Impact factor: 2.649

10.  Uptake, accumulation, and egress of erythromycin by tissue culture cells of human origin.

Authors:  J R Martin; P Johnson; M F Miller
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

View more
  38 in total

1.  Blood, tissue, and intracellular concentrations of erythromycin and its metabolite anhydroerythromycin during and after therapy.

Authors:  S Krasniqi; P Matzneller; M Kinzig; F Sörgel; S Hüttner; E Lackner; M Müller; M Zeitlinger
Journal:  Antimicrob Agents Chemother       Date:  2011-11-14       Impact factor: 5.191

2.  Non-peptide macrocyclic histone deacetylase inhibitors derived from tricyclic ketolide skeleton.

Authors:  Sandra C Mwakwari; William Guerrant; Vishal Patil; Shabana I Khan; Babu L Tekwani; Zachary A Gurard-Levin; Milan Mrksich; Adegboyega K Oyelere
Journal:  J Med Chem       Date:  2010-08-26       Impact factor: 7.446

3.  Neuroprotective Properties of a Macrolide Antibiotic in a Mouse Model of Middle Cerebral Artery Occlusion: Characterization of the Immunomodulatory Effects and Validation of the Efficacy of Intravenous Administration.

Authors:  Diana Amantea; Michelangelo Certo; Francesco Petrelli; Giacinto Bagetta
Journal:  Assay Drug Dev Technol       Date:  2016-07-08       Impact factor: 1.738

4.  Efficacy of macrolides and telithromycin against leptospirosis in a hamster model.

Authors:  James E Moon; Michael W Ellis; Michael C Ellis; Matthew E Griffith; Joshua S Hawley; Robert G Rivard; Suzanne McCall; Duane R Hospenthal; Clinton K Murray
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

5.  Macrolones Are a Novel Class of Macrolide Antibiotics Active against Key Resistant Respiratory Pathogens In Vitro and In Vivo.

Authors:  Hana Čipčić Paljetak; Donatella Verbanac; Jasna Padovan; Miroslava Dominis-Kramarić; Željko Kelnerić; Mihaela Perić; Mihailo Banjanac; Gabrijela Ergović; Nerrisa Simon; John Broskey; David J Holmes; Vesna Eraković Haber
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

6.  Blood, tissue, and intracellular concentrations of azithromycin during and after end of therapy.

Authors:  P Matzneller; S Krasniqi; M Kinzig; F Sörgel; S Hüttner; E Lackner; M Müller; M Zeitlinger
Journal:  Antimicrob Agents Chemother       Date:  2013-01-28       Impact factor: 5.191

Review 7.  Antibacterial and immunomodulatory properties of azithromycin treatment implications for periodontitis.

Authors:  P M Bartold; A H du Bois; S Gannon; D R Haynes; R S Hirsch
Journal:  Inflammopharmacology       Date:  2013-02-28       Impact factor: 4.473

Review 8.  Ketolides--the modern relatives of macrolides : the pharmacokinetic perspective.

Authors:  Markus Zeitlinger; Claudia Christina Wagner; Birgit Heinisch
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

9.  Concentration of the macrolide antibiotic tulathromycin in broncho-alveolar cells is influenced by comedication of rifampicin in foals.

Authors:  Monica Venner; Jette Peters; Nina Höhensteiger; Birthe Schock; Alexa Bornhorst; Markus Grube; Ulrike Adam; Eberhard Scheuch; Werner Weitschies; Dieter Rosskopf; Heyo K Kroemer; Werner Siegmund
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-12-15       Impact factor: 3.000

10.  Efficacy of clarithromycin against experimentally induced pneumonia caused by clarithromycin-resistant Haemophilus influenzae in mice.

Authors:  Shigeki Nakamura; Katsunori Yanagihara; Nobuko Araki; Koichi Yamada; Yoshitomo Morinaga; Koichi Izumikawa; Masafumi Seki; Hiroshi Kakeya; Yoshihiro Yamamoto; Shimeru Kamihira; Shigeru Kohno
Journal:  Antimicrob Agents Chemother       Date:  2009-11-30       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.